KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors

DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab, was well tolerated and demonstrated durable responses Dose was determined for Phase II expansion cohorts in 3rd line MSS-CRC and 2nd/3rd line NSCLC Data to be presented at ASCO 2023 MODI’IN, Israel, May 31, 2023 /PRNewswire/ —¬†KAHR, a clinical-stage biotech company developing … Read more